Investigational drug · Phase 2
valemetostat tosylate
Also called: DS-3201b
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Lung Cancer, Relapsed/Refractory Peripheral T-Cell Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
9
Any phase or sponsor naming "valemetostat tosylate"
First trial start
2019
May 20, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "valemetostat tosylate", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Lung Cancer
- Relapsed/Refractory Peripheral T-Cell Lymphoma
- Adult T Cell Leukemia/Lymphoma
- Lymphoma, Non-Hodgkin
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "valemetostat tosylate" as an intervention, largest first.
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT07303387 · 900 participants (planned) · Start Mar 5, 2026 · Primary completion Feb 28, 2031
Drug: Valemetostat Tosylate · For: Solid Tumor Malignancies; Clear Cell Endometrial Carcinoma; Ovarian Cancer
Sites: Villejuif, France; Bordeaux, France; Lyon, France · 4 sites in all
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT06632977 · 474 participants (planned) · Start Feb 6, 2025 · Primary completion Apr 11, 2030
Drug: Valemetostat Tosylate; Carboplatin and 4 more · For: Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
Sites: Birmingham, Alabama; Tucson, Arizona; Chico, California · 108 sites in all
- A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid TumorsActive, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06244485 · 210 participants (planned) · Start Feb 22, 2024 · Primary completion Nov 1, 2028
Drug: Valemetostat tosylate; T-DXd and 1 more · For: Advanced Solid Tumor
Sites: Irvine, California; San Diego, California; Plantation, Florida · 35 sites in all
- Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)Active, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT04703192 · 155 participants · Start Jun 3, 2021 · Primary completion May 10, 2023
Drug: Valemetostat Tosylate · For: Relapsed/Refractory Peripheral T-Cell Lymphoma; Adult T Cell Leukemia/Lymphoma
Sites: Duarte, California; Palo Alto, California; San Francisco, California · 60 sites in all
- Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell LymphomaActive, not recruiting
The Lymphoma Academic Research OrganisationAcademic, hospital or other
NCT04842877 · 141 participants (planned) · Start Jun 11, 2021 · Primary completion Dec 3, 2024
Drug: Valemetostat tosylate · For: Lymphoma, B-Cell
Sites: Bruges, Belgium; Ghent, Belgium; Verviers, Belgium · 22 sites in all
- A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsPivotal-lookingActive, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06644768 · 137 participants (planned) · Start Oct 30, 2024 · Primary completion Mar 30, 2028
Drug: valemetostat tosylate; pembrolizumab · For: Non-small Cell Lung Cancer; Lung Cancer
Sites: La Jolla, California; Los Angeles, California; Jacksonville, Florida · 35 sites in all
University of Alabama at BirminghamAcademic, hospital or other
NCT06294548 · 45 participants (planned) · Start Jul 29, 2025 · Primary completion Jan 30, 2028
Drug: Valemetostat; Atezolizumab and 1 more · For: Hepatocellular Carcinoma
Sites: Birmingham, Alabama
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
NCT04102150 · 25 participants · Start Nov 21, 2019 · Primary completion Apr 24, 2021
Drug: Valemetostat Tosylate · For: Adult T-cell Leukemia/Lymphoma
Sites: Nagoya, Japan; Kashiwa-shi, Japan; Tōon-shi, Japan · 24 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07862465
Drug: Valemetostat tosylate · For: Peripheral T-cell Lymphomas; Adult T-cell Leukemia/Lymphoma; Anaplastic Large Cell Lymphoma and 1 more
Newest research
PubMed records naming it or its code names, newest first.
- Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma.
Tachibana M, Horwitz S, Jacobsen E, et al. · Clin Transl Sci 2025
- Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A/P-gp Modulators.
Watanabe A, Okudaira N, Tachibana M, et al. · Clin Transl Sci 2025
- Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open-Label, Phase I Study.
Tachibana M, Craveiro TV, Marbury TC, et al. · Clin Pharmacol Drug Dev 2025
- Effect of Rifampicin on the Pharmacokinetics of Valemetostat and Its Primary Metabolite: A Phase 1 Study in Healthy Participants.
Tachibana M, Matsuki S, Kurata A, et al. · Clin Transl Sci 2025
- Toll-Interacting Protein Down-Regulation by Cigarette Smoke Exposure Impairs Human Lung Defense against Influenza A Virus Infection.
Agraval H, Gao J, Schaunaman N, et al. · Am J Pathol 2025
- Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding.
Tachibana M, Siebers N, Craveiro TV, et al. · Cancer Chemother Pharmacol 2025
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Daiichi Sankyo.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.